LQDA touts commercial growth and expanding clinical pipeline
YUTREPIA launch drove rapid revenue and patient growth, with adoption in PAH and PH-ILD. The company says its pipeline is expanding, including L606 for broader indications and improved tolerability, supporting sustained profitability.